Ajanta Pharma
Ajanta Pharma Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Ajanta Pharma
Start SIPAjanta Pharma Investment Rating
-
Master Rating:
-
Ajanta Pharma has an operating revenue of Rs. 3,742.64 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 20% is great, ROE of 17% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 5% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 59 which is a POOR score indicating inconsistency in earnings, a RS Rating of 56 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 104 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 849 | 875 | 837 | 850 | 766 |
| Operating Expenses Qtr Cr | 704 | 715 | 677 | 664 | 578 |
| Operating Profit Qtr Cr | 145 | 159 | 161 | 186 | 187 |
| Depreciation Qtr Cr | 32 | 32 | 32 | 31 | 30 |
| Interest Qtr Cr | 1 | 3 | 1 | 1 | 7 |
| Tax Qtr Cr | 31 | 31 | 39 | 40 | 43 |
| Net Profit Qtr Cr | 117 | 124 | 167 | 150 | 135 |
Ajanta Pharma Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 16
- Bearish Moving Average
- ___
- 0
- 20 Day
- ₹1294.91
- 50 Day
- ₹1272.89
- 100 Day
- ₹1253.98
- 200 Day
- ₹1249.54
- 20 Day
- ₹1289.11
- 50 Day
- ₹1270.36
- 100 Day
- ₹1231.73
- 200 Day
- ₹1249.74
Ajanta Pharma Resistance and Support
| Resistance | |
|---|---|
| First Resistance | ₹1326.19 |
| Second Resistance | ₹1338.62 |
| Third Resistance | ₹1355.29 |
| RSI | 63.37 |
| MFI | 78.95 |
| MACD Single Line | 9.47 |
| MACD | 11.4 |
| Support | |
|---|---|
| First Resistance | ₹1297.09 |
| Second Resistance | ₹1280.42 |
| Third Resistance | ₹1267.99 |
Ajanta Pharma Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 36,794 | 1,737,413 | 47.22 |
| Week | 74,235 | 5,134,065 | 69.16 |
| 1 Month | 117,381 | 8,861,088 | 75.49 |
| 6 Month | 98,075 | 5,693,252 | 58.05 |
Ajanta Pharma Result Highlights
Ajanta Pharma Synopsis
NSE-Medical-Generic Drugs
Ajanta Pharma Lt is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 3411.27 Cr. and Equity Capital is Rs. 25.27 Cr. for the Year ended 31/03/2023. Ajanta Pharma Ltd. is a Public Limited Listed company incorporated on 31/12/1979 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24230MH1979PLC022059 and registration number is 022059.| Market Cap | 16,656 |
| Sales | 3,411 |
| Shares in Float | 4.28 |
| No of funds | 197 |
| Yield | 0.53 |
| Book Value | 5.15 |
| U/D Vol ratio | 1.3 |
| LTDebt / Equity | |
| Alpha | 0.07 |
| Beta | 0.1 |
Ajanta Pharma
| Owner Name | Apr-23 | Mar-23 | Dec-22 | Sep-22 |
|---|---|---|---|---|
| Promoters | 66.21% | 66.11% | 66.11% | 70.48% |
| Mutual Funds | 13.72% | 13.77% | 13.57% | 11.14% |
| Insurance Companies | 1.36% | 1.3% | 1.28% | 1.01% |
| Foreign Portfolio Investors | 10.03% | 10% | 10.07% | 8.23% |
| Financial Institutions/ Banks | ||||
| Individual Investors | 6.95% | 7.1% | 7.18% | 7.31% |
| Others | 1.73% | 1.72% | 1.79% | 1.83% |
Ajanta Pharma Management
| Name | Designation |
|---|---|
| Mr. Mannalal B Agrawal | Chairman |
| Mr. Madhusudan B Agrawal | Vice Chairman |
| Mr. Yogesh M Agrawal | Managing Director |
| Mr. Rajesh M Agrawal | Joint Managing Director |
| Dr. Anjana Grewal | Independent Director |
| Mr. Chandrakant M Khetan | Independent Director |
| Mr. K H Viswanathan | Independent Director |
| Mr. Prabhakar R Dalal | Independent Director |
Ajanta Pharma Forecast
Price Estimates
Ajanta Pharma Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2023-05-05 | Audited Results | |
| 2023-03-10 | Buy Back of shares | |
| 2023-02-01 | Quarterly Results | |
| 2022-11-03 | Quarterly Results & Interim Dividend | |
| 2022-07-28 | Quarterly Results |
| Date | Purpose | Remarks |
|---|---|---|
| 2022-11-14 | INTERIM | Rs.7.00 per share(350%)Interim Dividend |
| 2021-11-10 | INTERIM | Rs.9.50 per share(475%)Interim Dividend |
| Date | Purpose | Remarks |
|---|---|---|
| 2022-06-23 | Bonus | Rs.0.00 issue in the ratio of 1:2 of Rs. 2/-. |
Ajanta Pharma FAQs
What is Share Price of Ajanta Pharma ?
Ajanta Pharma share price is ₹1322 As on 04 June, 2023 | 19:07
What is the Market Cap of Ajanta Pharma ?
The Market Cap of Ajanta Pharma is ₹16655.5 Cr As on 04 June, 2023 | 19:07
What is the P/E ratio of Ajanta Pharma ?
The P/E ratio of Ajanta Pharma is 28.3 As on 04 June, 2023 | 19:07
What is the PB ratio of Ajanta Pharma ?
The PB ratio of Ajanta Pharma is 4.9 As on 04 June, 2023 | 19:07